NADAC acquisition cost data for ALMOTRIPTAN MALATE 12.5 MG TAB. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00093526119 | $21.98 | 2022-12-21 | Rx |
| 00093526129 | $21.98 | 2022-12-21 | Rx |
| 00378524632 | $21.98 | 2022-12-21 | Rx |
| 00378524685 | $21.98 | 2022-12-21 | Rx |
| 27241004221 | $21.98 | 2022-12-21 | Rx |
| 27241004268 | $21.98 | 2022-12-21 | Rx |
| 00093526119 | $21.98 | 2022-12-21 | Rx |
| 00093526129 | $21.98 | 2022-12-21 | Rx |
| 00378524632 | $21.98 | 2022-12-21 | Rx |
| 00378524685 | $21.98 | 2022-12-21 | Rx |
Generic: Almotriptan Malate | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $2.0M | 6,221 | 1,529 | $24.12 |
| 2020 | $1.8M | 5,773 | 1,431 | $22.42 |
| 2021 | $1.7M | 5,407 | 1,362 | $22.36 |
| 2022 | $1.8M | 5,165 | 1,363 | $24.04 |
| 2023 | $1.7M | 4,839 | 1,289 | $24.22 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $161.6K | 530 | 151 |
| New York | $149.4K | 466 | 118 |
| Pennsylvania | $124.5K | 372 | 93 |
| Ohio | $101.4K | 181 | 43 |
| Florida | $92.1K | 247 | 69 |
| Massachusetts | $89.9K | 227 | 48 |
| Texas | $82.4K | 246 | 82 |
| Michigan | $67.0K | 165 | 48 |
| North Carolina | $66.6K | 197 | 51 |
| New Jersey | $59.4K | 130 | 33 |
| Kentucky | $57.1K | 161 | 28 |
| Indiana | $51.5K | 143 | 35 |
| Illinois | $50.8K | 126 | 33 |
| Washington | $50.6K | 116 | 42 |
| Wisconsin | $50.4K | 121 | 24 |
| Arizona | $45.7K | 104 | 30 |
| Missouri | $39.5K | 94 | 29 |
| Connecticut | $27.8K | 70 | 25 |
| Georgia | $27.8K | 72 | 20 |
| Virginia | $27.1K | 80 | 26 |
| Colorado | $26.8K | 78 | 17 |
| Tennessee | $23.4K | 66 | 22 |
| Alabama | $23.0K | 76 | 24 |
| Maryland | $22.2K | 77 | 24 |
| Oregon | $20.6K | 59 | 17 |
| Iowa | $18.1K | 47 | 15 |
| Puerto Rico | $17.0K | 57 | N/A |
| South Carolina | $16.4K | 58 | 18 |
| Idaho | $15.0K | 17 | N/A |
| Minnesota | $15.0K | 45 | 14 |
| Louisiana | $13.8K | 38 | N/A |
| Maine | $13.4K | 52 | 14 |
| New Hampshire | $13.0K | 40 | 12 |
| Nebraska | $8.3K | 18 | N/A |
| Utah | $8.1K | 27 | N/A |
| Kansas | $8.1K | 29 | N/A |
| West Virginia | $8.0K | 26 | N/A |
| Oklahoma | $7.0K | 24 | 12 |
| South Dakota | $6.9K | 19 | N/A |
| Nevada | $6.0K | 15 | N/A |
| Rhode Island | $5.9K | 24 | N/A |
| Vermont | $5.3K | 12 | N/A |
| Hawaii | $5.2K | 26 | N/A |
| Delaware | $4.3K | 21 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.